Abstract

Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been studied for their cardiovascular benefits in type 2 diabetes. Here, the authors show that GLP-1 RAs are associated with reduced mortality and improved cardio-renal outcomes in type 2 diabetes patients with acute kidney disease.

Details

Title
GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
Author
Pan, Heng-Chih 1 ; Chen, Jui-Yi 2   VIAFID ORCID Logo  ; Chen, Hsing-Yu 3 ; Yeh, Fang-Yu 4 ; Sun, Chiao-Yin 5 ; Huang, Thomas Tao-Min 6 ; Wu, Vin-Cent 6   VIAFID ORCID Logo 

1  College of Medicine, National Taiwan University, Graduate Institute of Clinical Medicine, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241); Chang Gung University College of Medicine, Taoyuan, Taiwan (GRID:grid.413801.f) (ISNI:0000 0001 0711 0593); Keelung Chang Gung Memorial Hospital, Division of Nephrology, Department of Internal Medicine, Keelung, Taiwan (GRID:grid.454209.e) (ISNI:0000 0004 0639 2551); Keelung Chang Gung Memorial Hospital, Community Medicine Research Center, Keelung, Taiwan (GRID:grid.454209.e) (ISNI:0000 0004 0639 2551); Linkou Chang Gung Memorial Hospital, Kidney Research Center and Department of Nephrology, Taoyuan, Taiwan (GRID:grid.454211.7) (ISNI:0000 0004 1756 999X) 
2  Chi Mei Medical Center, Division of Nephrology, Department of Internal Medicine, Tainan, Taiwan (GRID:grid.413876.f) (ISNI:0000 0004 0572 9255); Chia Nan University of Pharmacy and Science, Department of Health and Nutrition, Tainan, Taiwan (GRID:grid.411315.3) (ISNI:0000 0004 0634 2255) 
3  College of Medicine, Chang Gung University, Graduate Institute of Clinical Medical Sciences, Taoyuan, Taiwan (GRID:grid.145695.a) (ISNI:0000 0004 1798 0922); Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Division of Chinese Internal Medicine, Taoyuan, Taiwan (GRID:grid.413801.f) (ISNI:0000 0001 0711 0593); College of Medicine, Chang Gung University, School of Traditional Chinese Medicine, Taoyuan, Taiwan (GRID:grid.145695.a) (ISNI:0000 0004 1798 0922) 
4  National Taiwan University Hospital, Division of Nephrology, Primary Aldosteronism Center of Internal Medicine, Taipei, Taiwan (GRID:grid.412094.a) (ISNI:0000 0004 0572 7815) 
5  Keelung Chang Gung Memorial Hospital, Division of Nephrology, Department of Internal Medicine, Keelung, Taiwan (GRID:grid.454209.e) (ISNI:0000 0004 0639 2551); Linkou Chang Gung Memorial Hospital, Kidney Research Center and Department of Nephrology, Taoyuan, Taiwan (GRID:grid.454211.7) (ISNI:0000 0004 1756 999X) 
6  National Taiwan University Hospital, Division of Nephrology, Primary Aldosteronism Center of Internal Medicine, Taipei, Taiwan (GRID:grid.412094.a) (ISNI:0000 0004 0572 7815); and CAKS (Taiwan Consortium for Acute Kidney Injury and Renal Diseases), NSARF (National Taiwan University Hospital Study Group of ARF), Taipei, Taiwan (GRID:grid.412094.a) (ISNI:0000 0004 0572 7815) 
Pages
5912
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41467-024-50199-y
ProQuest document ID
3079907818
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.